Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) support people living with long covid, (b) retain the services provided by the long covid clinic and (c) develop systems of treatment and diagnosis to identify long covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England has invested £314 million since the start of the pandemic to provide care and support for people with long COVID. This includes establishing specialist clinics throughout England to assess adults, children, and young people who are experiencing the long-term effects of COVID-19 infection. A further £86.7 million of funding was included in integrated care board (ICB) core allocations for 2024/25, and specific regional funding was also allocated for assurance and system support.
These services offer physical, cognitive, and psychological assessment, and, where appropriate, refer patients onto existing services for treatment and rehabilitation. More information can be found via the NHS website at the following link:
https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/
The commissioning and service provision of long COVID services are the responsibility of local ICBs, which are allocated funding by NHS England to meet local needs and priorities and to improve outcomes.
Between 2019/20 and 2023/24, through the National Institute for Health and Care Research and the Medical Research Council, we have invested over £57 million on research into long COVID, with almost £40 million of this through two specific research calls on long COVID. The funded projects aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate the effectiveness of clinical care.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has had discussions with the University of Derby on the development of the drug Remdesivir for the treatment of long Covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We are aware of the University of Derby’s study looking at the use of the drug Remdesivir for the treatment of long COVID, however officials have not discussed the study with the research team. The study is being managed by the University of Plymouth’s Peninsula Clinical Trials Unit. Since 2008, the Department, through the National Institute for Health and Care Research, has funded clinical trials units in England to support developments in the design and delivery of efficient and innovative research. We will follow the progress of the study to understand the implications for policy and practice.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if his Department will take steps to ensure that non-mRNA covid vaccines are made available via the NHS to people unable to receive mRNA vaccines.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
All vaccines in the United Kingdom must be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) before they can be placed on the United Kingdom’s market. The updated 2024/25 Novavax (Nuvaxovid) COVID-19 vaccine has not been authorised by the MHRA.
The COVID-19 chapter of the publication, Immunisation against infectious diseases, also known as the Green Book, details that there are very few individuals who cannot receive the COVID-19 vaccines approved in the UK. The Green Book Chapter 14a can be found on the GOV.UK website, at the following link:
https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a
Published advice recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where vaccination is indicated, they could then be vaccinated in hospital under clinical supervision. NHS England will continue to follow this clinical guidance and offer mRNA vaccination under expert supervision in a hospital setting. This advice can be found at the following link:
https://www.nhs.uk/vaccinations/COVID-19-vaccine/
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance NHS England has issued to hospital trusts to ensure appropriate monitoring of individuals entering and leaving hospital wards; and how many reported security incidents relating to unauthorised access to wards there have been in the last five years.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England provides no guidance to National Health Service trusts to ensure the appropriate monitoring of individuals entering and leaving hospital wards, and data is not collected on how many reported security incidents relating to unauthorised access to wards there have been in the last five years. NHS trusts formulate policy at a local level to determine the best security for their estate.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) trust and (b) accountability on staff complaints in NHS organisations; and what steps he is taking to prevent (i) discrimination and (ii) bullying in the NHS.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
National Health Service staff should have the confidence to speak out and come forward if they have concerns. There is support in place for staff who wish to raise concerns, including a network of more than 1,200 local Freedom to Speak Up Guardians across healthcare in England, whose role it is to help and support NHS workers. In November 2024, the Department launched a consultation on options for regulating NHS managers, with the aim of improving leadership quality and accountability. This will help ensure that the NHS has strong and effective leadership in place, and that leaders and managers are held accountable for their practise.
Discrimination and bullying are unacceptable in any workplace and have no place in the NHS. All employers across the NHS should have robust policies in place on how these behaviours should be handled, and what support should be made available to staff.
In June 2023, NHS England published their Equality Diversity and Inclusion Improvement Plan, which set out a series of High Impact Actions, including the requirement for NHS organisations to review data by protected characteristics on bullying, harassment, discrimination, and violence, and to develop plans to improve staff experience. NHS England has also developed an NHS Civility and Respect programme to tackle bullying and harassment in the NHS, and to create a culture of civility and respect.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) engage healthcare professionals in the early diagnosis and treatment of facial palsy and (b) support patients in the days following a facial palsy diagnosis.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The provision of care and management for people with facial palsy, also known as Bell’s palsy, is the responsibility of general practices, under local integrated care boards.
The National Institute for Health and Care Excellence (NICE) has produced a clinical knowledge summary on Bell’s palsy, last revised in February 2023, which provides primary care practitioners with a readily accessible summary of the current evidence base and practical advice on best practice for Bell’s palsy. This clinical knowledge summary is available on the NICE’s website, at the following link:
https://cks.nice.org.uk/topics/bells-palsy/
Our 10-Year Health Plan will consider what actions are needed to improve patient access and reduce waiting times for patients, including those with facial or Bell’s palsy, by setting out a bold agenda to deliver on the big shifts needed, including the shift from the hospital to the community.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of including nanopore sequencing-based brain tumour methylome classification in the National Genomic Test Directory.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funded the Cancer 2.0 initiative in 2021, delivered by Genomics England in close partnership with NHS England. The three-year programme demonstrated that nanopore sequencing-based brain tumour classification demonstrates significant promise for the National Genomic Test Directory. Full validation is required before full clinical implementation can be considered.
Other genomic testing for brain cancer is already included in the National Genomic Test Directory. This testing can be delivered using a range of technologies, including whole genome sequencing (WGS) or Next Generation Sequencing (NGS) technology, namely large cancer gene panels, to ensure that a patient receives the most appropriate genomic testing depending on their individual circumstances.
To date no application has been made to NHS England to evaluate nanopore sequencing-based brain tumour methylome classification. If an application were received, NHS England would assess the evidence in line with the Test Directory policy.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support individuals living with Cauda Equina Syndrome with access to (a) treatment, (b) rehabilitation and (c) financial assistance.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the lives of those living with rare diseases, such as cauda equina syndrome. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include improving access to specialist care, treatments, and drugs. We remain committed to delivering under the Framework and published the annual England action plan in February 2025.
The Getting It Right First Time (GIRFT) programme is a national NHS England programme designed to improve the treatment and care of patients through in-depth review of services, benchmarking, and presenting a data-driven evidence base to support change.
GIRFT has worked collaboratively with a multidisciplinary group of more than 60 health professionals to develop an interactive pathway for those patients with suspected cauda equina syndrome, designed to support clinical teams to diagnose and treat the condition without delay and improve patient outcomes. The pathway offers best practice along all stages of the patient pathway, including post-operative care and best practice for surgical techniques, pain control and other post-operative support, which includes a section on finances. More information is available at the following link:
https://girft-interactivepathways.org.uk/cauda-equina-1/
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of communication systems between GP surgeries and pharmacies.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government recognises the importance of effective communication between general practice (GP) surgeries and pharmacies, to ensure safe and coordinated patient care. Over recent years, several digital initiatives have been introduced to reduce the reliance on fax and paper, and to enhance this communication, including NHSmail, the Electronic Prescription Service, and the Summary Care Record. These systems allow pharmacists to access patient information and support prescription processing.
GP Connect is a national service introduced in 2018, and further strengthened in the 2025/26 GP Contract, that allows authorised health and social care workers in a variety of care settings to access their patients' GP records. The aim of GP Connect is to support better, more joined-up clinical care by opening up information and data held within GP IT systems, so that registered community pharmacists can view and update records. This initiative supports the Pharmacy First service, which empowers pharmacists to offer a full consultation and provide treatment for seven common health conditions.
The Community Pharmacy Information Standard informed the plan to recover access to primary care published in May 2023. This set out a range of actions to improve communication between GP surgeries and community pharmacies, harnessing digital technology to streamline referrals, increase access to clinical information to support patient care and update the patient record in an efficient and timely way. The Government remains committed to strengthening primary care integration and to fixing the front door of the National Health Service.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment with Cabinet colleagues of the impact of patent lengths on research into treatments for glioblastoma.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Intellectual property rights in the United Kingdom are not condition specific. The Government considers the UK’s current patent system to strike the right balance between incentivising research and innovation and supporting access to medicines for the National Health Service.